Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

How patients experience the symptoms/signs of psoriasis is highly relevant for assessing treatment response.

[1]  A. Armstrong,et al.  Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial , 2018, The Journal of dermatological treatment.

[2]  M. Song,et al.  Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial , 2018, The British journal of dermatology.

[3]  A. Kimball,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial , 2017, Journal of the American Academy of Dermatology.

[4]  A. Armstrong,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA , 2017, Journal of the American Academy of Dermatology.

[5]  S. Feldman,et al.  Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary , 2016, The Journal of dermatological treatment.

[6]  J. McElwee,et al.  IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases , 2015, Nature Medicine.

[7]  P. Mease.  The Psoriasis Symptom Inventory: An Effective Patient-reported Outcome Measure of Psoriasis Severity , 2015, The Journal of Rheumatology.

[8]  B. Strober,et al.  The Psoriasis Symptom Diary: development and content validity of a novel patient‐reported outcome instrument , 2014, International journal of dermatology.

[9]  A. Armstrong,et al.  Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011 , 2012, PloS one.

[10]  S J Zyzanski,et al.  Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. , 1996, The Journal of investigative dermatology.

[11]  E. Coles,et al.  The effect of severe psoriasis on the quality of life of 369 patients , 1995, The British journal of dermatology.

[12]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[13]  S. Feldman,et al.  Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary ☆ , 2016 .

[14]  Nhs Trust.  A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis:Psoriasis Area and Severity Index,Physician's Global Assessment and Lattice System Physician's Global Assessment , 2006 .

[15]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.